ATAI Life Sciences atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Saved in:
Bibliographic Details
Published inNews Bites US - NASDAQ
Format Newsletter
LanguageEnglish
Published Melbourne News Bites Pty Ltd 14.04.2023
Subjects
Foreign exchange rates
Ketamine
Life sciences
Mental disorders
Mental health
Neurosciences
Present value
Stockholders
United States > US
Online AccessGet full text

Cover

More Information
Description not available.